The diagnosis of AML with TP53 mutation takes precedence over AML with myelodysplasia-related cytogenetic anomalies (AML-MRC) due to the poor prognosis TP53 mutations convey [10, 11]. This evidence concerns the gene TP53 and Myelodysplasia.